News

Capital Market on MSN8d
Biocon arm gets USFDA approval for insulin, Kirsty
Kirsty is biosimiler to Novolog. It is a rapid-acting human insulin analog indicated to improve glycemic control in adults ...
The Bakersfield Californian9d
Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only ...
BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE ...
Stocktwits on MSN8d
Buy Biocon, Zydus Life For Short-Term Gains, Says SEBI RA Vinayak Gautam After Fresh Regulatory Approvals
Biocon and Zydus Lifesciences are in the spotlight with fresh regulatory approvals fueling bullish analyst sentiment and renewed retail interest. Biocon shares rose 2% on Wednesday after its ...
Rediff Money8d
Biocon's Kirsty: USFDA Approval for Diabetes Drug
Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog. This rapid-acting insulin ...
BioWorld7d
Biocon wins first FDA interchangeable label of Novolog biosimilar
The U.S. FDA on July 15 cleared Biocon Biologics Ltd.’s Kirsty (insulin aspart-xjhz) as the first and only interchangeable ...
Trade Brains on MSN8d
Pharma stock jumps 4% after receiving USFDA approval for diabetes treatment drug
The shares of the prominent pharmaceutical company gained up to 4 percent in today's trading session after the company ...
Biocon Biologics Expands Diabetes Portfolio With FDA Approval Of Kirstytm, The First And Only Interchangeable Rapid-Acting Insulin Aspart In The United States
BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully int ...
Medical Dialogues8d
Biocon Biologics expands biosimilar insulin portfolio with USFDA nod of Kirsty
Karnataka: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...
The Pharma Letter8d
FDA approves Biocon BLA for Kirsty
The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin ...
Biocon Biologics gets USFDA nod for diabetes medication
Biocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes treatment. It is a rapid-acting insulin analog. The medication will be ...
Biocon Biologics expands diabetes portfolio with FDA approval for Kirsty
Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...